A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67-Reference-Cited by-同舟云学术

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67

Published:2017-03-07 Issue:15 Volume:23 Page:4035-4045
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Jovanović Bojana,Mayer Ingrid A.,Mayer Erica L.,Abramson Vandana G.,Bardia Aditya,Sanders Melinda E.,Kuba M. Gabriela,Estrada Monica V.,Beeler J. Scott,Shaver Timothy M.,Johnson Kimberly C.,Sanchez Violeta,Rosenbluth Jennifer M.,Dillon Patrick M.,Forero-Torres Andres,Chang Jenny C.,Meszoely Ingrid M.,Grau Ana M.,Lehmann Brian D.,Shyr Yu,Sheng Quanhu,Chen Sheau-Chiann,Arteaga Carlos L.,Pietenpol Jennifer A.

Funder

NIH

Komen for the Cure Foundation

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the Potential: Caloric Restriction, Caloric Restriction Mimetics, and Their Impact on Cancer Prevention and Treatment;Metabolites;2024-07-30

2. A holistic review of recent advances in nano-based drug delivery systems for the treatment of triple-negative breast cancer (TNBC);Journal of Nanoparticle Research;2024-05

3. Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium Compound;ACS Pharmacology & Translational Science;2024-04-05

4. Everolimus decreases [U-13C]glucose utilization by pyruvate carboxylase in breast cancer cells in vitro and in vivo;Biomedicine & Pharmacotherapy;2024-04

5. Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC;Cancer Letters;2024-04